Solid Biosciences Valuation
| SLDB Stock | USD 6.19 0.11 1.81% |
At this time, the company appears to be undervalued. Solid Biosciences LLC has a current Real Value of $8.52 per share. The regular price of the company is $6.19. Our model measures the value of Solid Biosciences LLC from inspecting the company fundamentals such as Shares Outstanding of 77.91 M, shares owned by institutions of 99.05 %, and Return On Equity of -0.87 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Solid Biosciences' valuation include:
Price Book 2.2092 | Enterprise Value | Enterprise Value Ebitda (3.69) | Price Sales 3.6454 | Enterprise Value Revenue 1.1559 |
Undervalued
Today
Please note that Solid Biosciences' price fluctuation is slightly risky at this time. Calculation of the real value of Solid Biosciences LLC is based on 3 months time horizon. Increasing Solid Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Solid Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Solid Stock. However, Solid Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.19 | Real 8.52 | Target 15.75 | Hype 6.18 |
The real value of Solid Stock, also known as its intrinsic value, is the underlying worth of Solid Biosciences LLC Company, which is reflected in its stock price. It is based on Solid Biosciences' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Solid Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Solid Biosciences LLC helps investors to forecast how Solid stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Solid Biosciences more accurately as focusing exclusively on Solid Biosciences' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Solid Biosciences' intrinsic value based on its ongoing forecasts of Solid Biosciences' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Solid Biosciences' closest peers. If more than one evaluation category is relevant for Solid Biosciences we suggest using both methods to arrive at a better estimate.
Solid Biosciences Cash |
|
Solid Biosciences Total Value Analysis
Solid Biosciences LLC is at this time forecasted to have valuation of 214.3 M with market capitalization of 428.51 M, debt of 24.18 M, and cash on hands of 162.88 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Solid Biosciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
214.3 M | 428.51 M | 24.18 M | 162.88 M |
Solid Biosciences Asset Utilization
One of the ways to look at asset utilization of Solid is to check how much profit was generated for every dollar of assets it reports. Solid Biosciences LLC has a negative utilization of assets of -0.44 %, losing $0.004367 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Solid Biosciences LLC shows how discouraging it operates for each dollar spent on its assets.Solid Biosciences Profitability Analysis
Based on Solid Biosciences' profitability indicators, Solid Biosciences LLC may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Solid Biosciences' ability to earn profits and add value for shareholders.Net Loss | First Reported 2015-12-31 | Previous Quarter -39.5 M | Current Value -45.8 M | Quarterly Volatility 9.6 M |
For Solid Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Solid Biosciences LLC to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Solid Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Solid Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Solid Biosciences over time as well as its relative position and ranking within its peers.
Solid Biosciences Earnings per Share Projection vs Actual
The next projected EPS of Solid Biosciences is estimated to be -0.527525 with future projections ranging from a low of -0.7325 to a high of -0.46. Solid Biosciences' most recent 12-month trailing earnings per share (EPS TTM) is at -2.48. Please be aware that the consensus of earnings estimates for Solid Biosciences LLC is based on EPS before non-recurring items and includes expenses related to employee stock options.Solid Biosciences Earnings Estimation Breakdown
The calculation of Solid Biosciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Solid Biosciences is estimated to be -0.527525 with the future projection ranging from a low of -0.7325 to a high of -0.46. Please be aware that this consensus of annual earnings estimates for Solid Biosciences LLC is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.73 Lowest | Expected EPS | -0.46 Highest |
Solid Biosciences Earnings Projection Consensus
Suppose the current estimates of Solid Biosciences' value are higher than the current market price of the Solid Biosciences stock. In this case, investors may conclude that Solid Biosciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Solid Biosciences' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 13 | 69.49% | -0.48 | -0.527525 | -2.48 |
Solid Biosciences Ownership Allocation
The majority of Solid Biosciences LLC outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Solid Biosciences to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Solid Biosciences LLC. Please pay attention to any change in the institutional holdings of Solid Biosciences LLC as this could imply that something significant has changed or is about to change at the company.Solid Biosciences Profitability Analysis
Net Loss for the year was (124.7 M) with loss before overhead, payroll, taxes, and interest of (96.43 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Solid Biosciences' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Solid Biosciences and how it compares across the competition.
About Solid Biosciences Valuation
The stock valuation mechanism determines Solid Biosciences' current worth on a weekly basis. Our valuation model uses a comparative analysis of Solid Biosciences. We calculate exposure to Solid Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Solid Biosciences's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -2.8 M | -2.7 M | |
| Pretax Profit Margin | (12.22) | (12.83) | |
| Operating Profit Margin | (15.12) | (15.88) | |
| Net Loss | (12.22) | (12.83) |
Solid Biosciences Current Valuation Indicators
Valuation refers to the process of determining the present value of Solid Biosciences LLC and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Solid we look at many different elements of the entity such as Solid's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Solid Biosciences, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Solid Biosciences' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Solid Biosciences' worth.Complementary Tools for Solid Stock analysis
When running Solid Biosciences' price analysis, check to measure Solid Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Solid Biosciences is operating at the current time. Most of Solid Biosciences' value examination focuses on studying past and present price action to predict the probability of Solid Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Solid Biosciences' price. Additionally, you may evaluate how the addition of Solid Biosciences to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |